Recruiting

Evaluation of the Acceptability, Appropriateness, and Feasibility/Usability of a Metastatic Breast-cancer Specific Prognostic Calculator Among Clinicians

ClinicalTrials.gov IDNCT05440929

PhaseNot Applicable

Enrollment15

SponsorUNC Lineberger Comprehensive Cancer Center

AgeNo minimum reported

SexALL

I'm interested View official listing

Conditions studied

Metastatic Breast Cancer, End of Life

About this study

I this qualitative study, Investigators will conduct semi-structured interviews with clinicians that are involved in the care of patients with breast cancer to evaluate the acceptability, appropriateness, and feasibility/usability of a metastatic breast cancer-specific prognostic tool. These interviews will be conducted by the UNC CHAI Core and will continue until thematic saturation (estimated 10 participants). The investigators will code the qualitative data using emerging themes, guided by a well-established implementation science theory, the Consolidated Framework for Implementation Research (CFIR). The information gained from these studies will inform an implementation approach to increase the usability and acceptability of a novel prognostic tool to assist oncologists in the prognosis of patients with metastatic breast cancer.

Interventions

Behavioral: Clinician Qualitative Interview — Interviews will be conducted by experienced qualitative researchers from the UNC Connected Health for Applications \& Interventions (CHAI) Core. The interview will be conducted over the phone or secure videoconferencing. The interview will be conducted in a semi-structured fashion using an interview guide. However, because the purpose of this semi-structured qualitative interview study is to determine which themes participants identify as important, the exact content of each interview will differ, and the interview guide will be modified as additional interviews are conducted. Interviews will be audio recorded with concurrent notetaking by the interviewer.

Primary outcomes

Key barriers for use a metastatic breast cancer-specific prognostic tool (12 months)
Key facilitators for use of a metastatic breast cancer-specific prognostic tool (12 months)

Eligibility information

Inclusion Criteria: 1. Verbal informed consent obtained to participate in the study. 2. Subject is willing and able to comply with study procedures based on the judgement of the investigator or protocol designee. 3. Physician, nurse practitioner, physician assistant, or nurse navigator 4. At least 6 months of experience in the clinical care of patients with metastatic breast cancer in the United States. Exclusion Criteria: * Non-English Speaking

Study locations

University of North Carolina, Chapel Hill, North Carolina 27599 United States

Before you participate: Varda Clinical is an independent discovery tool, not the study sponsor or a medical provider. Eligibility can only be determined by the official study team. Discuss potential risks and benefits with a qualified healthcare professional.

Source: ClinicalTrials.gov. Record last refreshed by Varda Clinical: 2026-09-27.